Eva Milz
Eva Milz, Medical Practice for Psychiatry and Psychotherapy, Berlin, Germany
Title: Social and curative aspects of treatment with Cannabis in adult ADHD
Biography
Biography: Eva Milz
Abstract
Background: Attention deficit hyperactivity disorder (ADHD) may persist into adulthood and
become treatment resistant to standard medication. Many patients report on a symptom relief
with Cannabis. Although with noticeable symptom reduction associated, their experience is
mainly restricted to THC-predominant blackmarket strains in unknown quality with the thread of
prosecution. Due to the change in german legislation, Cannabis flowers can be prescribed as a
narcotic medication, if guideline-therapy was ineffective or associated with intolerable side
effects. Aim of the analysis was to gain a first insight into the health-related and social
experiences of patients with adult ADHD, who medicate with prescribed Cannabis.
Methods: Analysis of 31 questionnaires from Cannabis-patients in a specialized psychiatric
practice between August 2017 and February 2018 regarding specific treatment aspects of adult
ADHD. The data included pre-treatment, specific social aspects, modes of application, average
daily dosages, grading of different Cannabis flowers and the use of Cannabidiol.
Results: With standardized cannabinoid medication patients experienced an improvement of
key symptoms and social status. Average single dose was 300 mg with a mean daily dosage of 2
grams split into 7 inhalations. A relevant amount of Cannabidiol in Cannabis Flowers led to a
positive influence on impulsiveness and agitation. Acceptance of Sativex® increased with
experience of a beneficial prolonged effect of oral intake and a relevant amount of CBD. Health
insurances reimburse costs in 1 of 4 cases, although all patients and future prescribing doctors
affirm a better quality of life.
Conclusion: Cannabis can be an effective treatment alternative in adult ADHD. Cannabidiol
alleviates impulsiveness and agitation. Best therapeutic results can be seen with an
individualized combination of oral and inhalative cannabinoid medication.